Interventional Cardiologist
John Muir Health Cardiovascular Institute
San Francisco, California, United States
Dr. Gershony is an interventional cardiologist who trained at Emory University under Andreas Gruentzig. He was the Director of Cardiovascular Research, Education and Technology at John Muir Health in the Bay Area until 2022. Dr. Gershony’s research interests include novel devices for complex angioplasty, percutaneous valve therapies and local drug-delivery to prevent restenosis. He has participated in numerous clinical trials as a PI and has authored over 100 manuscripts, patent applications and abstracts.
Dr. Gershony was the Founder of Vascular Solutions, which had a successful IPO and for which he served as CMO and a member of the BOD. He was also the Founder and CMO of AngioScore until its successful acquisition by Spectranetics/Philips.
Dr. Gershony is a founding General Partner of BayMed Venture Partners, which is focused on early stage Medical Device and Digital Health companies in the U.S. and Israel.
Disclosure information not submitted.
Sources of Funding for Early Stage Medical Device and Digital Health Companies
Sunday, March 10, 2024
8:16 AM – 8:24 AM ET
Panel Discussion | Challenges and Opportunities for Innovation in 2023
Sunday, March 10, 2024
9:12 AM – 9:27 AM ET
A Novel Completely Extravascular Temporary Pacing Lead System
Sunday, March 10, 2024
10:39 AM – 10:47 AM ET
Sunday, March 10, 2024
10:55 AM – 11:10 AM ET
Panel Discussion: What Does the Future Hold for Interatrial Shunts?
Monday, March 11, 2024
11:20 AM – 11:45 AM ET
Late-Breaking Artificial Intelligence Clinical Trials [Non-CME]
Monday, March 11, 2024
8:00 AM – 9:00 AM ET
A Novel Extravascular Temporary-to-Permanent Pacing Lead System
Tuesday, March 12, 2024
9:04 AM – 9:12 AM ET
Panel Discussion | Second- and Third-Generation Aortic Valve Systems Not Yet Approved in the US
Tuesday, March 12, 2024
9:36 AM – 10:15 AM ET